General Meeting

Buyout of Novartis’ interest in GlaxoSmithKline Consumer Healthcare Holdings Limited

At a General Meeting held on Thursday 3 May 2018 at the QEII Centre, Broad Sanctuary, Westminster, London SW1P 3EE, shareholders approved the proposed buyout of Novartis’ interest in GlaxoSmithKline Consumer Healthcare Holdings Limited. The voting results can be found here. The buyout completed on 1 June 2018 for $13 billion. 

The Circular to Shareholders and Notice of General Meeting (PDF) gives details on the resolution put to the meeting, together with explanatory notes.

Previously published documents relating to the approved transaction:

• Read the GSK press release dated 27 March 2018

Webcast dated 27 March 2018:

• Listen to the webcast
• View the webcast slides (PDF)
• View the webcast transcript (PDF)

In accordance with section 311A of the Companies Act 2006, GSK confirms that, as at 11 April 2018, its issued share capital (excluding Treasury shares) consisted of 4,959,130,058 ordinary shares of 25 pence each, carrying one vote each. Therefore, the total voting rights that members were entitled to exercise at the General Meeting in respect of these shares was 4,959,130,058.